Robert L. Hudkins

2.8k total citations
89 papers, 2.2k citations indexed

About

Robert L. Hudkins is a scholar working on Molecular Biology, Organic Chemistry and Immunology. According to data from OpenAlex, Robert L. Hudkins has authored 89 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Molecular Biology, 29 papers in Organic Chemistry and 26 papers in Immunology. Recurrent topics in Robert L. Hudkins's work include Receptor Mechanisms and Signaling (24 papers), Mast cells and histamine (21 papers) and Phenothiazines and Benzothiazines Synthesis and Activities (12 papers). Robert L. Hudkins is often cited by papers focused on Receptor Mechanisms and Signaling (24 papers), Mast cells and histamine (21 papers) and Phenothiazines and Benzothiazines Synthesis and Activities (12 papers). Robert L. Hudkins collaborates with scholars based in United States, Japan and France. Robert L. Hudkins's co-authors include John P. Mallamo, Thelma S. Angeles, Arup K. Ghose, Bruce D. Dorsey, Torsten Herbertz, Diane L. DeHaven‐Hudkins, Rita Raddatz, Michael S. Saporito, Ming Tao and Lisa D. Aimone and has published in prestigious journals such as Blood, Cancer Research and Analytical Biochemistry.

In The Last Decade

Robert L. Hudkins

85 papers receiving 2.0k citations

Peers

Countries citing papers authored by Robert L. Hudkins

Since Specialization

Citations

This map shows the geographic impact of Robert L. Hudkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert L. Hudkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert L. Hudkins more than expected).

Fields of papers citing papers by Robert L. Hudkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert L. Hudkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert L. Hudkins. The network helps show where Robert L. Hudkins may publish in the future.

Co-authorship network of co-authors of Robert L. Hudkins

This figure shows the co-authorship network connecting the top 25 collaborators of Robert L. Hudkins. A scholar is included among the top collaborators of Robert L. Hudkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert L. Hudkins. Robert L. Hudkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia 2025 ·JCI Insight ·Jacqueline H. Starrett, C. Lemoine, (unknown), (unknown), Nabil Kaci, (unknown), (unknown), (unknown), Qing Ye, My Chouinard, Eric Allen, Geneviève Baujat, Robert L. Hudkins, Michael B. Bober, Todd J. Harris, Ronald V. Swanson, (unknown)	1
2	Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia 2024 ·Journal of Medicinal Chemistry ·Robert L. Hudkins, Eric Allen, (unknown), Isaac Hoffman, (unknown), (unknown), Kirk Nelson, (unknown), Qing Ye, Jacqueline H. Starrett, (unknown), Todd J. Harris, Ronald V. Swanson, Daniel C. Bensen	10
3	Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor 2018 ·Cell chemical biology ·Amit Shraga, (unknown), (unknown), Payam Khoshkenar, Nicolas Germain, Khriesto A. Shurrush, Sílvia Carvalho, Liat Avram, Shira Albeck, Tamar Unger, Bruce A. Lefker, Chakrapani Subramanyam, Robert L. Hudkins, Amir Mitchell, Ziv Shulman, Takayoshi Kinoshita, Nir London	47
4	Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors 2016 ·Expert Opinion on Drug Discovery ·Thelma S. Angeles, Robert L. Hudkins	101
5	3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity 2015 ·European Journal of Medicinal Chemistry ·Robert L. Hudkins, (unknown), (unknown), Lisa D. Aimone, Mark A. Olsen, R. Curtis Haltiwanger, Joanne R. Mathiasen, Rita Raddatz, John A. Gruner	9
6	Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H3 receptor inverse agonists 2012 ·Bioorganic & Medicinal Chemistry Letters ·Kurt A. Josef, Lisa D. Aimone, (unknown), Rita Raddatz, Robert L. Hudkins	6
7	CEP-26401 (Irdabisant), a Potent and Selective Histamine H3 Receptor Antagonist/Inverse Agonist with Cognition-Enhancing and Wake-Promoting Activities 2011 ·Journal of Pharmacology and Experimental Therapeutics ·Rita Raddatz, Robert L. Hudkins, Joanne R. Mathiasen, John A. Gruner, Dorothy G. Flood, Lisa D. Aimone, (unknown), Hervé Schaffhauser, Emir Duzic, Maciej Gąsior, Donna Bozyczko‐Coyne, Michael J. Marino, Mark A. Ator, Edward R. Bacon, John P. Mallamo, Michael Williams	52
8	Synthesis and evaluation of 4-alkoxy-[1′-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4′-piperidine)] analogues as histamine-3 receptor antagonists 2011 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), (unknown), (unknown), Lisa D. Aimone, Rita Raddatz, Robert L. Hudkins	13
9	Identification of pyridazin-3-one derivatives as potent, selective histamine H3 receptor inverse agonists with robust wake activity 2011 ·Bioorganic & Medicinal Chemistry Letters ·Robert L. Hudkins, Lisa D. Aimone, T. R. Bailey, Robert J. Bendesky, (unknown), Derek Dunn, John A. Gruner, Kurt A. Josef, Yin‐Guo Lin, (unknown), Val R. Marcy, Joanne R. Mathiasen, (unknown), Ming Tao, Allison L. Zulli, Rita Raddatz, Edward R. Bacon	18
10	Synthesis and structure–activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists 2011 ·Bioorganic & Medicinal Chemistry Letters ·Ming Tao, Rita Raddatz, Lisa D. Aimone, Robert L. Hudkins	16
11	TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs 2008 ·Bioorganic & Medicinal Chemistry Letters ·Ted L. Underiner, Bruce Ruggeri, Lisa D. Aimone, Mark S. Albom, Thelma S. Angeles, Hong Chang, Robert L. Hudkins, Kathryn Hunter, Kurt A. Josef, Candy Robinson, (unknown), Shi Yang, Allison L. Zulli	8
12	CEP-11981: A potent TIE-2/Pan-VEGF-R inhibitor with broad kinase inhibitory activity exhibits significant antitumor and antiangiogenic efficacy in preclinical tumor models 2007 ·Molecular Cancer Therapeutics ·Bruce Ruggeri, Ted L. Underiner, Diane E. Gingrich, Robert L. Hudkins, Thelma S. Angeles, Mark S. Albom, Hong Chang, Candy Robinson, Kathryn Hunter, Paweł Dobrzański, Susan Jones‐Bolin, Lisa D. Aimone, Mark A. Ator, Jean‐Marc Herbert, Françoise Bono, Paul Schaefer, Pierre Casellas, (unknown), John P. Mallamo, Jeffry L. Vaught	2
13	Novel C-3 N-urea, amide, and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors 2006 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Allison L. Zulli, Thelma S. Angeles, Shi Yang, Mark S. Albom, Lisa D. Aimone, Candy Robinson, Hong Chang, Robert L. Hudkins	13
14	The selective PARP inhibitor, CEP-8983 exhibits significant chemosensitization in combination with TMZ and SN38 against chemoresistant tumor cell lines and xenografts 2005 ·Cancer Research ·Sheila Miknyoczki, (unknown), (unknown), Jennifer V. Grobelny, (unknown), (unknown), Allison L. Zulli, Mark A. Ator, Jean Husten, Robert L. Hudkins, Ralph E. Parchment, (unknown)	1
15	Synthesis and structure–activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors 2005 ·Bioorganic & Medicinal Chemistry Letters ·Ming Tao, (unknown), Ron Bihovsky, Gregory J. Wells, Jean Husten, Mark A. Ator, Robert L. Hudkins	41
16	Targeting the JNK Pathway for Therapeutic Benefit in CNS Disease 2002 ·PubMed ·Donna Bozyczko‐Coyne, Michael S. Saporito, Robert L. Hudkins	56
17	Prodrug esters of the indolocarbazole CEP-751 (KT-6587) 1998 ·Bioorganic & Medicinal Chemistry Letters ·Robert L. Hudkins, Mohamed Iqbal, (unknown), J. Goldstein, Joseph L. Herman, Efraim Shek, Chikara Murakata, John P. Mallamo	13
18	Enzyme-Linked Immunosorbent Assay for trkA Tyrosine Kinase Activity 1996 ·Analytical Biochemistry ·Thelma S. Angeles, (unknown), (unknown), Robert L. Hudkins, Robert M. Stephens, David R. Kaplan, Craig A. Dionne	36
19	RLH-033, a novel, potent and selective ligand for the σ1 recognition site 1994 ·European Journal of Pharmacology ·Robert L. Hudkins, Richard B. Mailman, Diane L. DeHaven‐Hudkins	6
20	M1 muscarinic antagonists interact with σ recognition sites 1991 ·Life Sciences ·Robert L. Hudkins, Diane L. DeHaven‐Hudkins	48

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact